Learn about the Top 50 Pharmaceutical Company in Bangladesh 2025, ranked by market performance, innovation, and industry impact according to latest insights and trends from Q1 MAT 2025 (April 2024 – March 2025) data.
Table of Contents
Introduction
The pharmaceutical industry in Bangladesh has continued its robust growth trajectory into 2025, firmly establishing itself as a key pillar of the national economy and a significant player in the global generics market. According to data for Q1 MAT 2025 (April 2024 – March 2025) and Q1 Quarter 2025 (January – March 2025), the Bangladesh pharma market has demonstrated sustained performance, reflecting increased domestic demand, export expansion, and greater healthcare awareness post-pandemic.
According to Q1 MAT 2025 (April 2024 to March 2025) data, the Bangladesh pharmaceutical market reached a total size of BDT 36,614.4 crore, reflecting a robust year-on-year (YoY) growth rate of 17.3%. For the first quarter of 2025 alone (January to March 2025), the market recorded a revenue of BDT 9,413.5 crore, representing a quarterly growth of 15.1% compared to Q1 2024. This consistent upward trajectory highlights the sector’s resilience and momentum, driven by strong domestic demand, wider access to healthcare services, and the continued expansion of high-demand therapeutic areas such as anti-diabetics, oncology, cardiovascular, and respiratory treatments. The figures underscore the industry’s stable performance and its critical role in supporting national healthcare objectives.
The Q1 MAT 2025 data offers a comprehensive 12-month snapshot of market dynamics, highlighting evolving therapeutic trends, top-performing companies, and the impact of regulatory developments. Meanwhile, Q1 Quarter 2025 data provides focused insights into short-term performance patterns, sales fluctuations, and seasonal demand variations over the latest three-month period. Together, these datasets present a detailed view of the market’s structure, growth drivers, and future outlook.
Market Share Dominance of Top Pharmaceutical Company in Bangladesh
Top 15 Pharmaceutical Company Control Almost 90 % of the Market
The pharma market in Bangladesh is highly concentrated among leading companies, with the top players commanding significant control over the industry. According to the latest 1Q MAT 2025 market data analysis, the top 15 pharma companies collectively sustain approximately 88.23% of the total market share, representing a substantial portion of the 36,614.4 Crore BDT market. This highlights the strong presence and influence of these companies within the national pharma sector.
Top 10 Pharmaceutical Company Control Over Three-Quarters of the Market
Focusing more narrowly, the top 10 pharma companies in Bangladesh hold an impressive 74.53% share of the total pharmaceutical market. This demonstrates that a relatively small group of companies dominate the majority of pharma sales and distribution in the country, reflecting both competitive positioning and market consolidation.
Top 5 Pharmaceutical Company Account for Over Half of the Market Share
At the very forefront, the top 5 pharmaceutical company alone sustain approximately 52.87% of the total pharma market share in Bangladesh. This concentration of market power among just five key players underscores their pivotal role in shaping market trends, pricing, and innovation within the pharmaceutical industry.
List of Top 50 Pharmaceutical Company in Bangladesh Q1 MAT 2025
This Table Chart contains top 50 pharmaceutical company as per Q1 MAT 2025 data.
Q1 MAT 2025 (Bangladesh Pharma Market) means: Market insights and performance data for the Bangladesh pharma industry, covering the last 12 months (April 2024 – March 2025), as reported by IQVIA and captured at the end of Q1 2025.
| Data according to : Q1 MAT 2025, 12 months (April 2024 – March 2025) | |||||
| Ranking (MAT) | Company Name | Total value (Cr. BDT) | Market Share (%) | Market Share Growth (%) | Company Growth (%) |
| 1 | SQUARE Pharmaceuticals PLC | 6,439.5 | 17.587 | +4.3 | +22.3 |
| 2 | Incepta Pharmaceuticals | 4,613.3 | 12.60 | +5.4 | +23.7 |
| 3 | Beximco Pharmaceuticals Ltd. | 3,458.0 | 9.444 | -1.5 | +15.7 |
| 4 | Healthcare Pharmaceuticals | 2,793.4 | 7.629 | +5.0 | +23.1 |
| 5 | Renata PLC | 2,054.0 | 5.610 | +12.2 | +31.8 |
| 6 | Eskayef Pharmaceuticals Ltd. | 1,743.1 | 4.761 | +6.5 | +25.0 |
| 7 | Opsonin Pharma | 1,730.0 | 4.725 | +2.8 | +20.9 |
| 8 | Aristopharma Ltd. | 1,559.8 | 4.260 | +3.2 | +21.2 |
| 9 | Popular Pharmaceuticals PLC | 1,482.9 | 4.050 | +19.1 | +39.7 |
| 10 | ACME Laboratories Ltd. | 1,417.4 | 3.871 | +2.9 | +20.7 |
| 11 | ACI Pharmaceuticals | 1,331.5 | 3.637 | -2.9 | +13.9 |
| 12 | Radiant Pharmaceuticals Ltd. | 1,284.9 | 3.509 | -3.8 | +12.9 |
| 13 | Drug International Ltd. | 1,005.7 | 2.747 | -16.2 | -1.7 |
| 14 | Unimed Unihealth Pharma Ltd. | 879.5 | 2.402 | -8.1 | +8.0 |
| 15 | Beacon Pharmaceuticals PLC | 510.6 | 1.395 | +1.5 | +19.6 |
| 16 | Novo Nordisk | 418.0 | 1.142 | -26.5 | -13.8 |
| 17 | NIPRO JMI Pharma Ltd. | 415.0 | 1.133 | -3.4 | +13.5 |
| 18 | Ziska Pharmaceuticals Ltd. | 373.6 | 1.020 | +1.0 | +18.0 |
| 19 | IBNA SINA Pharmaceuticals | 310.5 | 0.848 | -18.3 | -4.7 |
| 20 | Navana Pharmaceuticals PLC | 292.0 | 0.798 | +3.9 | +20.8 |
| 21 | Synovia Pharma PLC | 283.3 | 0.774 | -8.3 | +8.3 |
| 22 | Nuvista Pharma Ltd. | 279.3 | 0.763 | -3.8 | +13.5 |
| 23 | NOVARTIS | 255.7 | 0.698 | -15.7 | -1.1 |
| 24 | Roche Bangladesh | 254.2 | 0.694 | -5.5 | +11.3 |
| 25 | General Pharmaceuticals Ltd. | 237.9 | 0.649 | -52.6 | -44.5 |
| 26 | SUN Pharma | 233.8 | 0.638 | -24.7 | -11.5 |
| 27 | Orion Pharma Ltd. | 218.7 | 0.597 | -14.3 | +0.7 |
| 28 | Eli Lilly | 153.0 | 0.418 | -19.2 | -5.4 |
| 29 | SERVIER | 151.9 | 0.415 | -19.6 | -4.1 |
| 30 | SANDOZ | 68.5 | 0.187 | -20.8 | -9.8 |
| 31 | Everest Pharmaceuticals Ltd. | 52.2 | 0.143 | -12.5 | +3.5 |
| 32 | Labaid Pharma | 47.5 | 0.130 | -27.8 | -16.7 |
| 33 | Delta Pharma Ltd. | 34.8 | 0.095 | -37.5 | -29.3 |
| 34 | OSL Pharma Ltd. | 30.2 | 0.082 | -11.1 | +4.2 |
| 35 | Biopharma Ltd. | 29.9 | 0.082 | -33.3 | -17.4 |
| 36 | Pacific Pharmaceuticals Ltd. | 19.9 | 0.054 | -54.6 | -42.3 |
| 37 | Mundi Pharma BD PVT. Ltd. | 18.6 | 0.051 | -16.7 | +3.0 |
| 38 | DBL Pharma | 16.7 | 0.046 | +25.0 | +21.2 |
| 39 | Jenphar Bangladesh Ltd. | 16.6 | 0.045 | -28.6 | -25.1 |
| 40 | Pharmasia Limited | 16.6 | 0.045 | -16.7 | -15.6 |
| 41 | Pharmacil | 11.3 | 0.031 | +200.0 | +431.6 |
| 42 | Orion Infusion Ltd. | 10.9 | 0.030 | -50.0 | -45.3 |
| 43 | DUPHAR | 8.4 | 0.023 | -33.3 | -18.9 |
| 44 | Jayson Pharmaceuticals Ltd. | 8.1 | 0.022 | 0.0 | +13.5 |
| 45 | Globe Pharma | 7.8 | 0.021 | -66.7 | -60.5 |
| 46 | One Pharma Ltd. | 5.3 | 0.014 | 0.0 | +139.9 |
| 47 | Team Pharmaceuticals Ltd. | 5.0 | 0.014 | -66.7 | -38.4 |
| 48 | Goodman Pharmaceuticals Ltd. | 2.9 | 0.008 | 0.0 | -25.3 |
| 49 | White Horse Pharma Ltd. | 2.8 | 0.008 | -50.0 | -43.4 |
| 50 | Sharif Pharmaceuticals Ltd. | 2.3 | 0.006 | 0.0 | +1.0 |
| Total Value: | 36,614.4 Cr. BDT | 100 % | 17.3 % | ||
| Data Source: IQVIA | |||||
List of Top 50 Pharmaceutical Company in Bangladesh Q1 Qtr. 2025
This Table Chart contains top 50 pharmaceutical company as per Q1 Qtr. 2025 data.
Q1 Qtr. 2025 (Bangladesh Pharma Market) means: Market insights and performance data for the Bangladesh pharmaceutical industry, covering the last 3 months (January 2025 – March 2025), as reported by IQVIA and captured at the end of Q1 Qtr. 2025.
| Data according to : Q1 Qtr. 2025, 3 Months (January 2025 – March 2025) | |||||
| Ranking Q1 Qtr. | Company Name | Total value (Cr. BDT) | Market Share (%) | Market Share Growth (%) | Company Growth (%) |
| 1 | SQUARE Pharmaceuticals PLC | 1,728.8 | 18.37 | +5.8 | +21.8 |
| 2 | Incepta Pharmaceuticals | 1,242.8 | 13.20 | +12.3 | +29.3 |
| 3 | Beximco Pharmaceuticals Ltd. | 861.8 | 9.15 | -5.2 | +9.2 |
| 4 | Healthcare Pharmaceuticals | 698.8 | 7.42 | +2.9 | +18.4 |
| 5 | Renata PLC | 536.3 | 5.70 | +13.6 | +30.6 |
| 6 | Eskayef Pharmaceuticals Ltd. | 465.5 | 4.95 | +1.0 | +16.4 |
| 7 | Opsonin Pharma | 464.1 | 4.93 | +11.3 | +28.0 |
| 8 | Aristopharma Ltd. | 405.0 | 4.30 | -1.8 | +13.0 |
| 9 | ACME Laboratories Ltd. | 397.0 | 4.22 | +15.0 | +32.2 |
| 10 | Popular Pharmaceuticals PLC | 381.9 | 4.06 | +15.3 | +32.5 |
| 11 | ACI Pharmaceuticals | 359.6 | 3.82 | +3.0 | +18.5 |
| 12 | Radiant Pharmaceuticals Ltd. | 357.1 | 3.79 | +8.9 | +25.6 |
| 13 | Drug International Ltd. | 267.5 | 2.84 | -2.7 | +11.8 |
| 14 | Unimed Unihealth Pharma Ltd. | 184.4 | 1.94 | -30.3 | -19.8 |
| 15 | Beacon Pharmaceuticals PLC | 110.1 | 1.17 | -2.7 | -15.2 |
| 16 | NIPRO JMI Pharma Ltd. | 103.3 | 1.10 | -9.1 | +4.6 |
| 17 | Novo Nordisk | 83.7 | 0.89 | -43.7 | -35.3 |
| 18 | Ziska Pharmaceuticals Ltd. | 82.6 | 0.88 | -17.8 | -5.8 |
| 19 | IBNA SINA Pharmaceuticals | 70.9 | 0.75 | -27.9 | -16.6 |
| 20 | Roche Bangladesh | 70.6 | 0.75 | +1.4 | +16.0 |
| 21 | Nuvista Pharma Ltd. | 69.9 | 0.74 | -3.9 | +10.8 |
| 22 | Navana Pharmaceuticals PLC | 67.0 | 0.71 | -5.3 | +9.6 |
| 23 | Synovia Pharma PLC | 60.8 | 0.65 | -21.7 | -10.7 |
| 24 | NOVARTIS | 57.5 | 0.61 | -23.8 | +11.9 |
| 25 | SUN Pharma | 55.8 | 0.59 | -22.4 | -10.6 |
| 26 | Orion Pharma Ltd. | 48.4 | 0.51 | -28.2 | -17.3 |
| 27 | Eli Lilly | 35.4 | 0.38 | -11.6 | -0.3 |
| 28 | General Pharmaceuticals Ltd. | 34.3 | 0.36 | -71.4 | -66.7 |
| 29 | SERVIER | 32.4 | 0.34 | -34.6 | -23.2 |
| 30 | SANDOZ | 13.1 | 0.14 | -39.1 | -29.8 |
| 31 | Labaid Pharma | 9.0 | 0.10 | -37.5 | -32.7 |
| 32 | Everest Pharmaceuticals Ltd. | 8.8 | 0.09 | -35.7 | -24.4 |
| 33 | Delta Pharma Ltd. | 7.0 | 0.07 | -50.0 | -37.6 |
| 34 | OSL Pharma Ltd. | 6.8 | 0.07 | -12.5 | +4.6 |
| 35 | Mundi Pharma BD PVT. Ltd. | 5.1 | 0.05 | -28.6 | -7.3 |
| 36 | Biopharma Ltd. | 4.3 | 0.05 | -28.6 | -21.9 |
| 37 | Pharmacil | 3.7 | 0.04 | +999.0 | +809.2 |
| 38 | DBL Pharma | 2.9 | 0.03 | -40.0 | -24.9 |
| 39 | Pacific Pharmaceuticals Ltd. | 2.8 | 0.03 | -62.5 | -54.3 |
| 40 | Jenphar Bangladesh Ltd. | 2.7 | 0.03 | -50.0 | -44.8 |
| 41 | Pharmasia Limited | 2.6 | 0.03 | -40.0 | -29.1 |
| 42 | Jayson Pharmaceuticals Ltd. | 2.5 | 0.03 | 50.0 | +80.8 |
| 43 | DUPHAR | 1.8 | 0.02 | 0.0 | +9.4 |
| 44 | Orion Infusion Ltd. | 1.4 | 0.01 | -83.3 | -72.2 |
| 45 | One Pharma Ltd. | 1.1 | 0.01 | 999.0 | +302.2 |
| 46 | Globe Pharma | 0.9 | 0.01 | -66.7 | -63.9 |
| 47 | Team Pharmaceuticals Ltd. | 0.8 | 0.01 | -50.0 | -48.8 |
| 48 | Sharif Pharmaceuticals Ltd. | 0.4 | 0.004 | 0.0 | +13.0 |
| 49 | White Horse Pharma Ltd. | 0.4 | 0.004 | -100.0 | -64.5 |
| 52 | Goodman Pharmaceuticals Ltd. | 0.3 | 0.008 | 0.0 | -25.3 |
| Total Value: | 9,413.5 Cr. BDT | 100 % | 15.1 % | ||
| Data Source: IQVIA | |||||
Remarkable Growth of One Pharma and Pharmacil Limited in Q1 2025
It is quite noteworthy that in the first quarter session of 2025, among the top 50 pharmaceutical company, One Pharma and Pharmacil Limited have shown the most remarkable growth in both market share and overall company performance.
-One Pharma recorded a share growth of 999.0 and company growth of 302.2.
-Pharmacil Limited also achieved a share growth of 999.0, with an even more impressive company growth of 809.2.
This is an excellent development, especially considering that both companies were previously positioned towards the lower end of the top list and are relatively smaller players in the industry. Their performance serves as a strong motivation for other emerging or small-scale pharmaceutical companies aiming to scale up and compete in the national market.
What is the Top 10 Pharmaceutical Company in Bangladesh?
What is the Top 20 Pharmaceutical Company in Bangladesh?
Conclusion
The Bangladesh pharmaceutical market in Q1 MAT and Q1 Qtr. 2025 has showcased consistent growth, resilience, and dynamism. Top players such as Square, Incepta, Beximco, and Renata continue to lead the industry, while challengers like Healthcare Pharma and Eskayef are gaining ground with aggressive market strategies. Backed by strong local manufacturing, growing demand for chronic care, and favorable regulatory policies, the Bangladesh pharmaceutical industry remains one of the most promising sectors in South Asia for 2025 and beyond.
As Bangladesh prepares for the next phase—venturing deeper into biosimilars, novel drug delivery systems, and regulated market exports—the role of strategic R&D, skilled workforce, and robust regulatory practices will be pivotal. With continued policy support and investments in technology and quality assurance, Bangladesh is well on its way to becoming a global pharmaceutical hub.
Abdus Sobhan Salim is professional experienced pharmacist in pharmaceuticals, author and founder of pharmabossbd.com, the Bangladeshi pharmaceutical blogger since 2019.
